by Randy E. Miller | May 28, 2025 | FDA, FOIA, Hedge Funds, Medical Devices, Stock Market
FOIAengine: Multiple Hedge Funds Seeking Inspection Reports Leading medical device manufacturer Insulet Corporation’s stock price (NASDAQ: PODD) is on a roll. But that hasn’t stopped financial firms from monitoring the company’s Food and Drug Administration plant...
by John A. Jenkins | May 14, 2025 | FOIA, Law Firms, Litigation, Politics, Short-Selling, Stock Market
FOIAengine Tracks the High Cost of Getting Even, and the Rewards Until six weeks ago, Jason Galanis was Inmate 80739-198 at the federal prison in Montgomery, Alabama, sentenced to almost 16 years confinement after admitting to a wild scheme in which he swindled tens...
by John A. Jenkins | May 8, 2025 | FDA, FOIA, FTC, News Media, SEC
The Latest Requests Logged in FOIAengine Questions about GLP-1 weight loss drugs, DOGE, cryptocurrencies, and the past conduct of Trump’s regulatory nominees are among those in newly available Freedom of Information Act requests filed by media organizations with the...
by John A. Jenkins | Apr 30, 2025 | FOIA, Law Firms, Litigation, Non-Profits, Politics
FOIAengine: Heritage’s Oversight Project Probes Law Firm Ties to Biden Amid President Trump’s recent high-profile efforts to punish or extract concessions from major law firms, a second front, much less publicized, has opened, with organizers of Project 2025 using the...
by Randy E. Miller | Apr 23, 2025 | FDA, FOIA, Hedge Funds, Pharmaceuticals
FOIAengine: Questions Seek Adverse Reports about Carvykti According to a new PoliScio Analytics analysis of early 2025 Freedom of Information Act requests, investment firm Point72 has launched a significant FOIA-driven investigation into Johnson &...
by John A. Jenkins | Apr 9, 2025 | FDA, FOIA, Medical Devices, Pharmaceuticals
FOIAengine: Revolving Door Hits Pfizer on the Way Out The revolving door between the Food and Drug Administration and the pharmaceutical industry took another fast spin when Pfizer announced that Patrizia Cavazzoni would be returning to the company as its chief...
